in ophthalmology

Allergan has been a world leader in ophthalmology for more than half a century. Our breakthrough RESTASIS® product pioneered a whole new market as the first and only therapeutic for treating chronic dry eye due to decreased tear production. Chronic dry eye is one of the most common complaints seen by eye doctors, but until RESTASIS® there was little that could be done for these patients beyond offering palliative therapy. It is currently estimated that approximately 4 to 5 million Americans have dry eye — a number expected to increase as the population ages⁽¹⁾. And our ALPHAGAN® product was the first alpha-2 agonist approved for the long-term treatment of elevated intraocular pressure and ocular hypertension. Our LUMIGAN® product, one of the most potent drugs to lower intraocular pressure, which has become the fourth largest glaucoma drug worldwide (by sales)⁽²⁾ is another key growth driver in this high-growth specialty market. Looking to the future, a major strategic focus in our pipeline for this business is on back-of-the-eye diseases such as macular edema, diabetic retinopathy and age-related macular degeneration, the leading cause of blindness in developed countries⁽³⁾.

in neurosciences

BOTOX® is the foundation for our global leadership position in neuromodulator therapy, and it continues to demonstrate versatility based on more than 15 years of successful clinical experience in therapeutic and aesthetic applications. The success of this product provides dramatic evidence that our focus on R&D and leadership in specialty markets has the potential to create strong return on investment. Initially approved for only limited indications, BOTOX® has become a blockbuster franchise for us and is now approved for 20 different indications in more than 75 countries. In the top 10 markets of the world, our estimated share of the neuromodulator market is approximately 90 percent⁽⁴⁾. Building on our leadership in botulinum toxin research, we are investigating potential new uses for BOTOX® in the treatment of chronic daily headache, overactive bladder, post-stroke spasticity, benign prostatic hypertrophy and pain management.

in medical aesthetics

Our acquisition of Inamed diversifies our revenues, adds a complementary portfolio of premier brands and creates a world-leading medical aesthetics franchise. It builds on our established leadership position in medical aesthetics with BOTOX® Cosmetic/VISTABEL®/VISTABEX™ and enables us to offer a broad and unique mix of products and services to our customers and their patients, including dermal fillers, breast augmentation devices and obesity interventions. Inamed’s BioEnterics® LAP-BAND® System (LAP-BAND®) is currently the only minimally invasive surgical approach in the United States to treating obesity. The LAP-BAND® (laparoscopic adjustable gastric band) is also the second-most-common bariatric procedure in the United States⁽⁵⁾, and a leading bariatric procedure worldwide, having been implanted in more than 200,000 patients. This will become a key specialty market for our company as obesity is the second-leading preventable cause of death and is today considered the most prevalent epidemic in the United States and a public health crisis throughout the world.

in medical dermatology

Because of our deep expertise in retinoids and alpha hydroxy acids, we are a leading company in the medical dermatology sector. Current growth drivers for this business include TAZORAC® and BOTOX® for hyperhidrosis. TAZORAC® was the first product fully developed by Allergan from “molecule to market.” This flagship product has become the fastest-growing topical retinoid for acne in the United States⁽⁶⁾ and is marketed in a growing number of international markets as ZORAC®. This year we added PREVAGE® MD (the most potent antioxidant currently available in a skin care product⁽⁷⁾) to our M.D. FORTE® physician-dispensed line. Furthermore, in 2006, we will be offering a new glycolic acid line, providing patients with a true continuum of care for the health of their skin.